A Phase 3 interventional study of denosumab and denosumab in Low Bone Mineral Density, Osteopenia and Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-31.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 13th largest by enrollment, is one of 3 that started in 2007, is one of 24 in phase 3, and was the 9th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 311 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 12th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2007, is one of 18 in phase 3, and was the 9th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density (BMD).
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
This study's enrollment of 311 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have successfully completed the 20050141 study (NCT00330460):
Exclusion Criteria:
Any disorder that, in the opinion of the investigator, may compromise the ability of the patient to give written and/or comply with study procedures including:
Any clinical evidence, in the medical judgement of the investigator, of the following medical conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
Biological: denosumab
Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
Biological: denosumab
Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6
An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.
Time frame: 6 months
Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12
An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.
Time frame: 12 months
Number of Participants With Neutralizing Antibodies Against Denosumab at Month 12
Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.
Time frame: Month 12
Sodium Change From Baseline at Month 1
Laboratory chemistry sodium
Time frame: Baseline, month 1
Sodium Change From Baseline at Month 6
Laboratory chemistry sodium
Time frame: Baseline, month 6
Sodium Change From Baseline at Month 12
Sodium Change From Baseline at Month 12
Time frame: Baseline, Month 12
Potassium Change From Baseline at Month 1
Laboratory chemistry potassium
Time frame: Baseline, month 1
Potassium Change From Baseline at Month 6
Laboratory chemistry potassium
Time frame: Baseline, month 6
Potassium Change From Baseline at Month 12
Laboratory chemistry potassium
Time frame: Baseline, month 12
Chloride Change From Baseline at Month 1
Laboratory chemistry chloride
Time frame: Baseline, month 1
Chloride Change From Baseline at Month 6
Laboratory chemistry chloride
Time frame: Baseline, month 6
Chloride Change From Baseline at Month 12
Laboratory chemistry chloride
Time frame: Baseline, month 12
Bicarbonate Change From Baseline at Month 1
Laboratory chemistry bicarbonate
Time frame: Baseline, month 1
Bicarbonate Change From Baseline at Month 6
Laboratory chemistry bicarbonate
Time frame: Baseline, month 6
Bicarbonate Change From Baseline at Month 12
Laboratory chemistry bicarbonate
Time frame: Baseline, month 12
Magnesium Change From Baseline at Month 1
Laboratory chemistry magnesium
Time frame: Baseline, month 1
Magnesium Change From Baseline at Month 6
Laboratory chemistry magnesium
Time frame: Baseline, month 6
Magnesium Change From Baseline at Month 12
Laboratory chemistry magnesium
Time frame: Baseline, month 12
Blood Urea Nitrogen Change From Baseline at Month 1
Laboratory chemistry blood urea nitrogen
Time frame: Baseline, month 1
Blood Urea Nitrogen Change From Baseline at Month 6
Laboratory chemistry blood urea nitrogen
Time frame: Baseline, month 6
Blood Urea Nitrogen Change From Baseline at Month 12
Laboratory chemistry blood urea nitrogen
Time frame: Baseline, month 12
Creatinine Change From Baseline at Month 1
Laboratory chemistry creatinine
Time frame: Baseline, month 1
Creatinine Change From Baseline at Month 6
Laboratory chemistry creatinine
Time frame: Baseline, month 6
Creatinine Change From Baseline at Month 12
Laboratory chemistry creatinine
Time frame: Baseline, month 12
Aspartate Amino Transferase Change From Baseline at Month 1
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 1
Aspartate Amino Transferase Change From Baseline at Month 6
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 6
Aspartate Amino Transferase Change From Baseline at Month 12
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 12
Alanine Amino Transferase Change From Baseline at Month 1
Laboratory chemistry alanine amino transferase
Time frame: Baseline, month 1
Alanine Amino Transferase Change From Baseline at Month 6
Laboratory chemistry alanine amino transferase
Time frame: Baseline, month 6
Alanine Amino Transferase Change From Baseline at Month 12
Laboratory chemistry alanine amino transferase
Time frame: Baseline, month 12
Total Bilirubin Change From Baseline at Month 1
Laboratory chemistry total bilirubin
Time frame: Baseline, month 1
Total Bilirubin Change From Baseline at Month 6
Laboratory chemistry total bilirubin
Time frame: Baseline, month 6
Total Bilirubin Change From Baseline at Month 12
Laboratory chemistry total bilirubin
Time frame: Baseline, month 12
Albumin Change From Baseline at Month 1
Laboratory chemistry albumin
Time frame: Baseline, month 1
Albumin Change From Baseline at Month 6
Laboratory chemistry albumin
Time frame: Baseline, month 6
Albumin Change From Baseline at Month 12
Laboratory chemistry albumin
Time frame: Baseline, month 12
Total Protein Change From Baseline at Month 1
Laboratory chemistry total protein
Time frame: Baseline, month 1
Total Protein Change From Baseline at Month 6
Laboratory chemistry total protein
Time frame: Baseline, month 6
Total Protein Change From Baseline at Month 12
Laboratory chemistry total protein
Time frame: Baseline, month 12
Glucose Change From Baseline at Month 1
Laboratory chemistry glucose
Time frame: Baseline, month 1
Glucose Change From Baseline at Month 6
Laboratory chemistry glucose
Time frame: Baseline, month 6
Glucose Change From Baseline at Month 12
Laboratory chemistry glucose
Time frame: Baseline, month 12
Red Blood Cells Change From Baseline at Month 1
Laboratory hematology red blood cells
Time frame: Baseline, month 1
Red Blood Cells Change From Baseline at Month 6
Laboratory hematology red blood cells
Time frame: Baseline, month 6
Red Blood Cells Change From Baseline at Month 12
Laboratory hematology red blood cells
Time frame: Baseline, month 12
Hemoglobin Change From Baseline at Month 1
Laboratory hematology hemoglobin
Time frame: Baseline, month 1
Hemoglobin Change From Baseline at Month 6
Laboratory hematology hemoglobin
Time frame: Baseline, month 6
Hemoglobin Change From Baseline at Month 12
Laboratory hematology hemoglobin
Time frame: Baseline, month 12
Reticulocytes Change From Baseline at Month 1
Laboratory hematology reticulocytes
Time frame: Baseline, month 1
Reticulocytes Change From Baseline at Month 6
Laboratory hematology reticulocytes
Time frame: Baseline, month 6
Reticulocytes Change From Baseline at Month 12
Laboratory hematology reticulocytes
Time frame: Baseline, month 12
Platelets Change From Baseline at Month 1
Laboratory hematology platelets
Time frame: Baseline, month 1
Platelets Change From Baseline at Month 6
Laboratory hematology platelets
Time frame: Baseline, month 6
Platelets Change From Baseline at Month 12
Laboratory hematology platelets
Time frame: Baseline, month 12
White Blood Cells Change From Baseline at Month 1
Laboratory hematology white blood cells
Time frame: Baseline, month 1
White Blood Cells Change From Baseline at Month 6
Laboratory hematology white blood cells
Time frame: Baseline, month 6
White Blood Cells Change From Baseline at Month 12
Laboratory hematology white blood cells
Time frame: Baseline, month 12
Total Neutrophils Change From Baseline at Month 1
Laboratory hematology total neutrophils
Time frame: Baseline, month 1
Total Neutrophils Change From Baseline at Month 6
Laboratory hematology total neutrophils
Time frame: Baseline, month 6
Total Neutrophils Change From Baseline at Month 12
Laboratory hematology total neutrophils
Time frame: Baseline, month 12
Eosinophils Change From Baseline at Month 1
Laboratory hematology eosinophils
Time frame: Baseline, month 1
Eosinophils Change From Baseline at Month 6
Laboratory hematology eosinophils
Time frame: Baseline, month 6
Eosinophils Change From Baseline at Month 12
Laboratory hematology eosinophils
Time frame: Baseline, month 12
Basophils Change From Baseline at Month 1
Laboratory hematology basophils
Time frame: Baseline, month 1
Basophils Change From Baseline at Month 6
Laboratory hematology basophils
Time frame: Baseline, month 6
Basophils Change From Baseline at Month 12
Laboratory hematology basophils
Time frame: Baseline, month 12
Lymphocytes Change From Baseline at Month 1
Laboratory hematology lymphocytes
Time frame: Baseline, month 1
Lymphocytes Change From Baseline at Month 6
Laboratory hematology lymphocytes
Time frame: Baseline, month 6
Lymphocytes Change From Baseline at Month 12
Laboratory hematology lymphocytes
Time frame: Baseline, month 12
Monocytes Change From Baseline at Month 1
Laboratory hematology monocytes
Time frame: Baseline, month 1
Monocytes Change From Baseline at Month 6
Laboratory hematology monocytes
Time frame: Baseline, month 6
Monocytes Change From Baseline at Month 12
Laboratory hematology monocytes
Time frame: Baseline, month 12
Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3
Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
Time frame: Day 1 to Month 12
Patients who successfully completed Study 20050141 (NCT00330460) were eligible to participate in this study. First Subject Enrolled: 30-May-2007 Last Subject Enrolled: 10-Sep-2007
| Milestone | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Started | 155 | 156 |
| Received study medication | 154 | 156 |
| Completed | 141 | 142 |
| Not completed | 14 | 14 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Lost to follow-up | 6 | 5 |
| Withdrew: Other | 0 | 1 |
An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.
| Participants | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6 | 0 | 0 |
An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.
| Participants | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12 | 0 | 0 |
Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.
No measurements were reported for this outcome.
Laboratory chemistry sodium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Sodium Change From Baseline at Month 1 | -0.1 ± 2.0 | 0.1 ± 1.7 |
Laboratory chemistry sodium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Sodium Change From Baseline at Month 6 | -1.2 ± 2.0 | -0.9 ± 1.8 |
Sodium Change From Baseline at Month 12
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Sodium Change From Baseline at Month 12 | -0.9 ± 2.1 | -0.6 ± 2.0 |
Laboratory chemistry potassium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Potassium Change From Baseline at Month 1 | 0.02 ± 0.37 | 0 ± 0.39 |
Laboratory chemistry potassium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Potassium Change From Baseline at Month 6 | 0.01 ± 0.43 | -0.07 ± 0.40 |
Laboratory chemistry potassium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Potassium Change From Baseline at Month 12 | 0.07 ± 0.40 | 0.04 ± 0.40 |
Laboratory chemistry chloride
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Chloride Change From Baseline at Month 1 | -0.1 ± 2.1 | 0.2 ± 1.9 |
Laboratory chemistry chloride
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Chloride Change From Baseline at Month 6 | -0.9 ± 2.3 | -0.4 ± 2.0 |
Laboratory chemistry chloride
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Chloride Change From Baseline at Month 12 | -0.2 ± 2.1 | 0 ± 2.5 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Bicarbonate Change From Baseline at Month 1 | -0.3 ± 2.9 | 0 ± 2.9 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Bicarbonate Change From Baseline at Month 6 | 0.2 ± 2.7 | 0.1 ± 2.9 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Bicarbonate Change From Baseline at Month 12 | -0.6 ± 2.8 | -0.1 ± 2.8 |
Laboratory chemistry magnesium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Magnesium Change From Baseline at Month 1 | 0.001 ± 0.092 | -0.010 ± 0.080 |
Laboratory chemistry magnesium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Magnesium Change From Baseline at Month 6 | -0.053 ± 0.073 | -0.064 ± 0.080 |
Laboratory chemistry magnesium
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Magnesium Change From Baseline at Month 12 | -0.053 ± 0.062 | -0.055 ± 0.074 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Blood Urea Nitrogen Change From Baseline at Month 1 | 0.01 ± 1.30 | -0.04 ± 1.38 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Blood Urea Nitrogen Change From Baseline at Month 6 | 0.09 ± 1.40 | 0.11 ± 1.49 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Blood Urea Nitrogen Change From Baseline at Month 12 | 0.27 ± 1.44 | -0.02 ± 1.50 |
Laboratory chemistry creatinine
| umol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Creatinine Change From Baseline at Month 1 | 0.24 ± 8.01 | 0.12 ± 7.76 |
Laboratory chemistry creatinine
| umol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Creatinine Change From Baseline at Month 6 | -0.19 ± 8.52 | -1.29 ± 8.23 |
Laboratory chemistry creatinine
| umol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Creatinine Change From Baseline at Month 12 | 1.40 ± 9.53 | 0.76 ± 8.28 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Aspartate Amino Transferase Change From Baseline at Month 1 | -1.6 ± 13.0 | 0.4 ± 4.7 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Aspartate Amino Transferase Change From Baseline at Month 6 | -1.6 ± 13.9 | 0.9 ± 7.7 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Aspartate Amino Transferase Change From Baseline at Month 12 | -1.9 ± 13.5 | 0.2 ± 3.9 |
Laboratory chemistry alanine amino transferase
| U/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Alanine Amino Transferase Change From Baseline at Month 1 | -3.1 ± 25.7 | 0.5 ± 5.5 |
Laboratory chemistry alanine amino transferase
| U/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Alanine Amino Transferase Change From Baseline at Month 6 | -1.4 ± 27.8 | 4.2 ± 15.2 |
Laboratory chemistry alanine amino transferase
| U/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Alanine Amino Transferase Change From Baseline at Month 12 | -2.7 ± 28.8 | 1.5 ± 6.3 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Bilirubin Change From Baseline at Month 1 | -0.35 ± 2.53 | -0.02 ± 2.47 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Bilirubin Change From Baseline at Month 6 | -0.30 ± 2.54 | -0.20 ± 2.67 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Bilirubin Change From Baseline at Month 12 | 0.16 ± 2.68 | 0.64 ± 2.74 |
Laboratory chemistry albumin
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Albumin Change From Baseline at Month 1 | -0.46 ± 1.68 | -0.40 ± 2.05 |
Laboratory chemistry albumin
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Albumin Change From Baseline at Month 6 | -0.34 ± 1.92 | -0.51 ± 2.19 |
Laboratory chemistry albumin
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Albumin Change From Baseline at Month 12 | -0.26 ± 1.82 | 0 ± 2.03 |
Laboratory chemistry total protein
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Protein Change From Baseline at Month 1 | -0.59 ± 2.67 | -0.54 ± 3.45 |
Laboratory chemistry total protein
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Protein Change From Baseline at Month 6 | -0.58 ± 3.00 | -0.80 ± 3.33 |
Laboratory chemistry total protein
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Protein Change From Baseline at Month 12 | -1.35 ± 2.84 | -0.91 ± 3.28 |
Laboratory chemistry glucose
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Glucose Change From Baseline at Month 1 | -0.08 ± 1.27 | 0.03 ± 0.69 |
Laboratory chemistry glucose
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Glucose Change From Baseline at Month 6 | -0.08 ± 1.37 | 0.05 ± 0.80 |
Laboratory chemistry glucose
| mmol/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Glucose Change From Baseline at Month 12 | -0.06 ± 1.27 | 0.08 ± 0.92 |
Laboratory hematology red blood cells
| 10^12/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Red Blood Cells Change From Baseline at Month 1 | 0 ± 0.21 | 0.02 ± 0.23 |
Laboratory hematology red blood cells
| 10^12/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Red Blood Cells Change From Baseline at Month 6 | 0.04 ± 0.22 | 0.04 ± 0.22 |
Laboratory hematology red blood cells
| 10^12/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Red Blood Cells Change From Baseline at Month 12 | -0.01 ± 0.22 | 0.02 ± 0.23 |
Laboratory hematology hemoglobin
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Hemoglobin Change From Baseline at Month 1 | -0.97 ± 6.00 | -0.42 ± 6.24 |
Laboratory hematology hemoglobin
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Hemoglobin Change From Baseline at Month 6 | 0.84 ± 5.83 | 0.96 ± 6.34 |
Laboratory hematology hemoglobin
| g/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Hemoglobin Change From Baseline at Month 12 | -1.74 ± 6.09 | -0.22 ± 6.62 |
Laboratory hematology reticulocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Reticulocytes Change From Baseline at Month 1 | 3.70 ± 17.68 | 1.69 ± 17.41 |
Laboratory hematology reticulocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Reticulocytes Change From Baseline at Month 6 | 19.54 ± 19.22 | 15.21 ± 20.69 |
Laboratory hematology reticulocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Reticulocytes Change From Baseline at Month 12 | 19.09 ± 19.82 | 15.08 ± 19.73 |
Laboratory hematology platelets
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Platelets Change From Baseline at Month 1 | 5.24 ± 33.20 | 2.48 ± 36.20 |
Laboratory hematology platelets
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Platelets Change From Baseline at Month 6 | 28.26 ± 32.16 | 21.49 ± 53.82 |
Laboratory hematology platelets
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Platelets Change From Baseline at Month 12 | 25.19 ± 42.07 | 15.60 ± 41.82 |
Laboratory hematology white blood cells
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| White Blood Cells Change From Baseline at Month 1 | 0.23 ± 1.07 | 0.01 ± 1.26 |
Laboratory hematology white blood cells
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| White Blood Cells Change From Baseline at Month 6 | 0.22 ± 1.38 | -0.08 ± 1.47 |
Laboratory hematology white blood cells
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| White Blood Cells Change From Baseline at Month 12 | 0.47 ± 1.38 | 0.24 ± 1.47 |
Laboratory hematology total neutrophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Neutrophils Change From Baseline at Month 1 | 0.11 ± 0.85 | -0.03 ± 1.10 |
Laboratory hematology total neutrophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Neutrophils Change From Baseline at Month 6 | 0.21 ± 1.23 | -0.02 ± 1.23 |
Laboratory hematology total neutrophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Total Neutrophils Change From Baseline at Month 12 | 0.38 ± 1.15 | 0.12 ± 1.18 |
Laboratory hematology eosinophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Eosinophils Change From Baseline at Month 1 | -0.002 ± 0.065 | -0.010 ± 0.059 |
Laboratory hematology eosinophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Eosinophils Change From Baseline at Month 6 | 0.020 ± 0.075 | 0.013 ± 0.104 |
Laboratory hematology eosinophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Eosinophils Change From Baseline at Month 12 | -0.008 ± 0.071 | 0.025 ± 0.436 |
Laboratory hematology basophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Basophils Change From Baseline at Month 1 | 0.001 ± 0.025 | 0 ± 0.022 |
Laboratory hematology basophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Basophils Change From Baseline at Month 6 | 0.012 ± 0.026 | 0.012 ± 0.028 |
Laboratory hematology basophils
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Basophils Change From Baseline at Month 12 | 0.003 ± 0.026 | 0.006 ± 0.024 |
Laboratory hematology lymphocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Lymphocytes Change From Baseline at Month 1 | 0.12 ± 0.43 | 0.04 ± 0.40 |
Laboratory hematology lymphocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Lymphocytes Change From Baseline at Month 6 | 0.01 ± 0.37 | -0.06 ± 0.45 |
Laboratory hematology lymphocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Lymphocytes Change From Baseline at Month 12 | 0.08 ± 0.41 | 0.06 ± 0.36 |
Laboratory hematology monocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Monocytes Change From Baseline at Month 1 | 0 ± 0.12 | 0.01 ± 0.11 |
Laboratory hematology monocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Monocytes Change From Baseline at Month 6 | -0.03 ± 0.14 | -0.03 ± 0.10 |
Laboratory hematology monocytes
| 10^9/L | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Monocytes Change From Baseline at Month 12 | 0.01 ± 0.13 | 0.03 ± 0.14 |
Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
| Participants | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| Number of patients with CTCAE grade 3 or 4 | 2 | 2 |
| Sodium - Grade 3 below normal (< 130 - 120 mmol/L) | 0 | 1 |
| Potassium - Grade 3 above normal (>6.0-7.0 mmol/L) | 0 | 1 |
| Magnesium -Grade 3 above normal (>1.23-3.30mmol/L) | 2 | 0 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab - Vial | — | 7/154 (4.5%) | 32/154 (20.8%) |
| Denosumab - Pre-filled Syringe | — | 12/156 (7.7%) | 49/156 (31.4%) |
| Event | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| PneumoniaInfections and infestations | 0/154 | 2/156 |
| Atrial fibrillationCardiac disorders | 1/154 | 1/156 |
| Cardiac failure congestiveCardiac disorders | 1/154 | 0/156 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/154 | 0/156 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/154 | 1/156 |
| Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/154 | 0/156 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/154 | 0/156 |
| Vaginal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/154 | 0/156 |
| Uterine prolapseReproductive system and breast disorders | 1/154 | 0/156 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/154 | 0/156 |
| Event | Denosumab - Vial | Denosumab - Pre-filled Syringe |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/154 | 13/156 |
| Back painMusculoskeletal and connective tissue disorders | 9/154 | 11/156 |
| Upper respiratory tract infectionInfections and infestations | 5/154 | 10/156 |
| SinusitisInfections and infestations | 5/154 | 8/156 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 3/154 | 8/156 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/154 | 8/156 |
| Age Continuous(Years) | Denosumab - Vial | Denosumab - Pre-filled Syringe | Total |
|---|---|---|---|
| Mean | 62.5 ± 8.5 | 62.9 ± 8.9 | 62.7 ± 8.7 |
| Sex: Female, Male(Participants) | Denosumab - Vial | Denosumab - Pre-filled Syringe | Total |
|---|---|---|---|
| Female | 155 | 156 | 311 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Denosumab - Vial | Denosumab - Pre-filled Syringe | Total |
|---|---|---|---|
| White or Caucasian | 124 | 131 | 255 |
| Black or African American | 4 | 1 | 5 |
| Hispanic or Latino | 24 | 18 | 42 |
| Asian | 3 | 3 | 6 |
| Japanese | 0 | 2 | 2 |
| American Indian or Alaska Native | 0 | 1 | 1 |
No study locations are listed for this record.
The record gives a start of May 2007, a primary completion of Mar 2008 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 5 years 7 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab